May 13
Current report
8-K
Events of May 12
Regulation FD disclosure
MTRI · InMed Pharmaceuticals Inc. · Documents
$18.79
+0.44 (+2.37%)
At close · Nov 13
Return incl. dividend (before tax)
Q4 2021 earnings call transcript
Going-concern doubt
— flagged Nov 3, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.”View the 10-Q filed Nov 3, 2026
Market Cap
$8.58M
Shares
549,374
Volume · Nov 13
7698
Avg daily vol (6 sessions)
62.9K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
May 12
Quarterly report
10-Q
FY2025 Q3, ended Mar 31
Quarterly report for FY2025 Q3
Revenue $1.26M
▲ 7.6%
Net loss $2.12M
Diluted EPS -$1.94
Apr 29
Proxy statement
PRE 14A
Proxy statement
Apr 25
Current report
8-K
Other events
Apr 8
Current report
8-K
Events of Apr 4
Other events
Feb 14
Current report
8-K
Events of Feb 10
Director or officer change, or executive pay, Regulation FD disclosure
Feb 13
Current report
8-K
Events of Feb 12
Regulation FD disclosure
Feb 12
Quarterly report
10-Q
FY2025 Q2, ended Dec 31
Quarterly report for FY2025 Q2
Revenue $1.11M
▼ 10.4%
Net loss $2.58M
Diluted EPS -$3.64
Feb 3
Current report
8-K
Regulation FD disclosure
Jan 22
Current report
8-K
Regulation FD disclosure
Jan 21
Current report
8-K
Regulation FD disclosure
2024
Dec 30
Registration statement
S-1/A
Registration statement
Dec 23
Registration statement
S-1
Registration statement
Dec 19
Current report
8-K
Events of Dec 18
Shareholder vote results, Regulation FD disclosure
Dec 18
Current report
8-K
Events of Dec 13
Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure
Nov 20
Current report
8-K
Events of Nov 19
Regulation FD disclosure
Nov 15
Current report
8-K
Events of Nov 14
Regulation FD disclosure
Nov 14
Quarterly report
10-Q
FY2025 Q1, ended Sep 30
Quarterly report for FY2025 Q1
Revenue $1.26M
▲ 40.2%
Net loss $1.68M
Diluted EPS -$2.71
Nov 12
Current report
8-K
Events of Nov 8
Change to shareholders' rights, Regulation FD disclosure, Other events
Nov 5
Current report
8-K
Events of Nov 1
Delisting notice or listing transfer, Regulation FD disclosure
Oct 28
Proxy statement
DEF 14A
Meeting Dec 18, 2024
Proxy statement
Oct 28
Current report
8-K
Regulation FD disclosure
Oct 28
Proxy statement
DEFA14A
Proxy statement
Oct 24
Current report
8-K
Regulation FD disclosure
Oct 23
Current report
8-K
Events of Oct 22
Regulation FD disclosure
Sep 30
Current report
8-K
Regulation FD disclosure
Sep 30
Annual report
10-K
FY2024, ended Jun 30
Annual report for FY2024
Revenue $4.6M
▲ 11.2%
Net loss $7.68M
Diluted EPS -$1.01
Sep 26
Current report
8-K
Other events
Sep 20
Current report
8-K
Events of Sep 17
Delisting notice or listing transfer, Regulation FD disclosure
Aug 21
Current report
8-K
Regulation FD disclosure
Aug 20
Current report
8-K
Regulation FD disclosure
Jul 30
Current report
8-K
Regulation FD disclosure
Jun 28
Current report
8-K
Events of Jun 27
Entered into a material agreement
Jun 11
Current report
8-K
Events of Jun 10
Regulation FD disclosure
May 14
Current report
8-K
Regulation FD disclosure
May 14
Quarterly report
10-Q
FY2024 Q3, ended Mar 31
Quarterly report for FY2024 Q3
Apr 18
Current report
8-K
Regulation FD disclosure
Apr 16
Current report
8-K
Regulation FD disclosure
Apr 5
Current report
8-K
Events of Apr 4
Regulation FD disclosure
Mar 20
Current report
8-K
Events of Mar 19
Delisting notice or listing transfer, Regulation FD disclosure
Feb 14
Current report
8-K
Events of Feb 13
Regulation FD disclosure
Feb 13
Quarterly report
10-Q
Ended Dec 31
Quarterly report for the period ended Dec 31, 2023
Revenue $1.24M
▲ 164.0%
Net loss $1.48M
Diluted EPS -$0.19
Feb 9
Current report
8-K
Events of Feb 8
Director or officer change, or executive pay, Regulation FD disclosure
Jan 19
Current report
8-K
Events of Jan 18
Regulation FD disclosure
Jan 16
Current report
8-K
Regulation FD disclosure
2023
Dec 21
Annual report
10-K/A
Ended Jun 30
Annual report for the period ended Jun 30, 2023
Dec 20
Current report
8-K
Events of Dec 19
Shareholder vote results, Regulation FD disclosure
Nov 29
Current report
8-K
Regulation FD disclosure
Nov 14
Current report
8-K
Other events
Nov 14
Quarterly report
10-Q
FY2024 Q1, ended Sep 30
Quarterly report for FY2024 Q1
Revenue $901.86K
▲ 181.1%
Net loss $2.54M
Diluted EPS -$0.76
Showing 51–100 of 247 documents